“No Evidence” Exists That Ephedra Ban Shifted Burden Of Proof, Agency Says
This article was originally published in The Tan Sheet
Executive Summary
No evidence has been presented that FDA's use of a risk/benefit analysis in its decision to ban ephedra shifted the burden of proof onto industry, the agency says